TriangleNCT00356031 · OUTCOME
Change in Median Microvessel Density (MVD) After Bevacizumab Alone
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- percentage of change in MVD
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- baseline and 3 years
What was measured
The percentage change in median microvessel density (MVD) after Bevacizumab treatment alone
Groups in this outcome
Bevacizumab, Radiation, and Surgery
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
| Group | Source count |
|---|---|
| Bevacizumab, Radiation, and Surgery | 20 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bevacizumab, Radiation, and Surgery | 53 | Not reported | 28.6 | 77.4 | Not reported |
Source statistical analyses
- group Ids
- OG000
- non Inferiority Type
- OTHER
- p Value
- <.05
- statistical Method
- t-test, 1 sided
Complete source fields
- analyses
- group Ids
- OG000
- non Inferiority Type
- OTHER
- p Value
- <.05
- statistical Method
- t-test, 1 sided
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 28.6
- upper Limit
- 77.4
- value
- 53
- denoms
- counts
- group Id
- OG000
- value
- 20
- units
- Participants
- description
- The percentage change in median microvessel density (MVD) after Bevacizumab treatment alone
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
- id
- OG000
- title
- Bevacizumab, Radiation, and Surgery
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- baseline and 3 years
- title
- Change in Median Microvessel Density (MVD) After Bevacizumab Alone
- type
- SECONDARY
- unit Of Measure
- percentage of change in MVD
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice